ReviewArchives of toxicology2024
Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies.
Review in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Spatiotemporal immunomodulation with programmable biomaterials to promote musculoskeletal tissue regeneration.Bioactive materials · 2026Review
- Review
- Synergistic application of concentrated growth factor and bone perforation technique in bisphosphonate-related-osteonecrosis of the jaw.BMC oral health · 2026Article
- Graphene-Based 3D Scaffolds in Bone Regeneration: Emerging Opportunities for MRONJ Treatment.Pharmaceutics · 2026Review
- Photobiomodulation Modulates the Response of Zoledronic-Acid-Treated Osteoblast-like SaOs-2 Cells: Implications for Bisphosphonate-Related Osteonecrosis.Bioengineering (Basel, Switzerland) · 2026Article
- Human umbilical cord-derived mesenchymal stem cells/Bio-Oss granules composite prevents medication-related osteonecrosis of the jaw in a rat model.Frontiers in bioengineering and biotechnology · 2026Article
- Double-edged-sword effect of bisphosphonates on the osteogenic differentiation of human periodontal ligament stem cells.Frontiers in pharmacology · 2026Article
- Targeting ferroptosis to rescue osteogenic differentiation in BRONJ-affected jawbone mesenchymal stem cells: the role of miR-145-3p and exosome-mediated therapy.Journal of nanobiotechnology · 2025Article
- Novel standardized method for inducing medication-related osteonecrosis of the jaw in rats and precise quantitative assessment of pathological outcomes.Odontology · 2025Article
- A GelMA/polydopamine hydrogel with PTH and osteogenically stimulated alveolar mucosa-derived stem cells promotes bone regeneration in MRONJ-affected wounds.Stem cell research & therapy · 2025Article
- Long-Term Follow-Up of a Patient with McCune-Albright Syndrome: A Case Report.Journal of clinical medicine · 2025Article
- Photobiomodulation in Medication-Related Osteonecrosis of the Jaw: Outcomes in Stage I and Its Adjunctive Role in Advanced Cases.Biomedicines · 2025Article
- Insights into Medication-Induced Osteonecrosis of the Jaw Through the Application of Salivary Proteomics and Bioinformatics.International journal of molecular sciences · 2024Article
- Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension?Healthcare (Basel, Switzerland) · 2024Review
- Secukinumab Causing Medication-Related Osteonecrosis of the Jaw, in a Patient Diagnosed with Psoriasis and Rheumatoid Arthritis.Psoriasis (Auckland, N.Z.) · 2024Article
- Exosomes from Adipose-Derived Mesenchymal Stromal Cells Prevent Medication-Related Osteonecrosis of the Jaw by Inhibiting Macrophage M1 Polarization and Pyroptosis.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Medication-related osteonecrosis of the jaw (MRONJ), a severe side effect caused by antiresorptive antiangiogenic medication, particularly bisphosphonates (BPs), has become a challenging disease with serious and profound effects on the physical and mental health of patients. Although it occurs with high frequency and is harmful, the exact mechanism of MRONJ remains unknown, and systematic and targeted approaches are still lacking. Maxillofacial surgeons focus on the etiology of osteonecrosis in the mandible and maxilla as well as the appropriate oral interventions for high-risk patients. Adequate nursing care and pharmacotherapy management are also crucial. This review provides a current overview of the clinicopathologic feature and research of MRONJ caused by BPs, with an emphasis on the potential mechanisms and current therapy and prevention strategies of the disease. We are of the opinion that an in-depth comprehension of the mechanisms underlying MRONJ will facilitate the development of more precise and efficacious therapeutic approaches, resulting in enhanced clinical outcomes for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.